EHA 2024: Updates in the Treatment of CLL    - Episode 10

BTKi Intolerance in Real-world Practice & Management Strategy

, , , ,

Key opinion leaders compare and contrast the most frequently observed causes of BTK inhibitor intolerance in clinical practice among patients treated with ibrutinib, acalabrutinib, or zanubrutinib.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024
    EP. 2: Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL
    EP. 3: Frontline BTKi Selection
    EP. 4: Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib
    EP. 5: Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy
    EP. 6: Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL
    EP. 7: EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches
    EP. 8: Navigating Treatment Approaches for R/R CLL
    EP. 9: How Experts View MAIC Data That was Presented at EHA 2024
    Now Viewing
    EP. 10: BTKi Intolerance in Real-world Practice & Management Strategy
    EP. 11: Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities
    EP. 12: Approach to Hypertension Management With BTKi Treatment
    EP. 13: Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib
    EP. 14: Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing
    EP. 15: Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice
    EP. 16: TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices
    EP. 17: EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL
    EP. 18: Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673
    EP. 19: Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL
    EP. 20: Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies
    EP. 21: Clinical Pearls and Impacts to Practice from EHA 2024
    1. What is the most common cause of BTKi intolerance you observe in the practice setting among patients receiving ibrutinib? Acalabrutinib or Zanubrutinib?
      1. At what point during treatment does intolerance typically occur?Dr davids @39:30 – dose reduce...once per day...tyr to get back up to full dose and rechallenge with acala.
      2. When may BTKi intolerance impact continuation of therapy and how do you manage these scenarios?
        1. Zanu in pts with acala/ibr intolerance – Shadman, et al. EHA 2023. Abs P633 
        2. Acala in pts with ibr intolerance – Rogers, et al. Haematologica. 2021;106(9):2364-2373
    x